image credit: Freepik

FDA Lifts Partial Clinical Hold on PRS-343 Phase 1 Studies

January 19, 2021

Via: BioSpace

Pieris, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the previously announced partial clinical hold on the phase 1 studies of PRS-343. As previously guided, the Company intends to move into a proof-of-concept study of PRS-343 in gastroesophageal cancer.

Read More on BioSpace